Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT04118114
Previous Study | Return to List | Next Study

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04118114
Recruitment Status : Recruiting
First Posted : October 8, 2019
Last Update Posted : June 13, 2022
Information provided by (Responsible Party):
National Cancer Centre, Singapore

Brief Summary:

This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy. Approximately 30 patients will be recruited with ~10 gastric cancers and ~10 hepatocellular carcinomas. Patients who have received at least 1 dose of PRL3-ZUMAB will be evaluable for toxicity and efficacy.

PRL3-ZUMAB will be given IV every 2 weeks for up to 12 infusions in the absence of unmanageable toxicities or disease progression. Patients who are benefitting from the treatment may continue on PRL3-ZUMAB beyond 12 infusions with the agreement of the study drug provider.

PRL3-ZUMAB at the RP2D in tumour types enriched for known PRL-3 expression for efficacy and tolerability will be evaluated. There will also be in depth molecular profiling of tissues in patients who have an objective response or prolonged disease stabilization to identify predictive/selection biomarkers as well as evaluation of the oncogenic signaling modulation and immunomodulation by PRL3-ZUMAB and its potential for future combination with other targeted therapies or immunotherapy.

Condition or disease Intervention/treatment Phase
Gastric Cancer Hepatocellular Carcinoma Advanced Solid Tumor Drug: PRL3-zumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase II Study of the Efficacy and Tolerability of PRL3-ZUMAB and Predictive Biomarkers in Advanced Solid Tumours
Actual Study Start Date : September 3, 2019
Estimated Primary Completion Date : June 2024
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PRL3-ZUMAB Monotherapy Drug: PRL3-zumab
IV administration every 2 weeks

Primary Outcome Measures :
  1. Objective response rate [ Time Frame: From start of treatment to first occurence of disease progression or death, up to 2 years ]
  2. Number of patients that do not have disease progression at 16 weeks from start of treatment [ Time Frame: 16 weeks after start of treatment ]
    Clinical benefit rate at 16 weeks

  3. Treatment related adverse events rate [ Time Frame: From start of treatment to 30 days after last dose of study drug ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients 21 years of age or older at the time written informed consent is obtained.
  • Histopathological- or cytological- documented advanced curatively unresectable solid tumors failing standard therapy.

    • For HCC must have failed at least 1 line of standard therapy.
    • For gastric cancer must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment).
    • For other solid tumours must have failed at least 1 line of standard therapy.
  • Progressive disease following the last treatment
  • Life expectancy ≥ 4 months
  • Eastern Cooperative Oncology Group (ECOG) performance status (ECOG PS) score of ≤ 2 at study entry
  • Recovery to Grade ≤ 1 by the Common Terminology Criteria for Adverse Events, Version 4.03 (CTCAE v 4.03), from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other targeted therapies for cancer, with the exception of non-clinically significant adverse events such as alopecia; biochemical abnormalities, or resolved to Grade ≤ 2: peripheral neuropathy; hypertension and proteinuria.
  • Women of childbearing potential (WOCBP) must have a negative pregnancy test at study entry. Subjects not considered WOCBP are those without menses for 24 consecutive months, and those who have undergone hysterectomy and/or bilateral salpingo-oophorectomy. WOCBP must be willing to use acceptable methods of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, or condom with spermicide, or abstinence) for the duration of the study.
  • Adequate organ and hematological function as evidenced by the following laboratory studies within 10 days of 1st treatment:

    • Absolute neutrophil count ≥ 1.0 x 10^9/L.
    • Platelet count ≥ 75 x 10^9/L. Hemoglobin ≥ 9 g/dL.
    • Prothrombin time and activated partial thromboplastin time ≤ 1.5 x upper limit of normal (ULN) per institutional laboratory normal range.
    • Total bilirubin ≤ 1.5x ULN.
    • Aspartate aminotransferase and alanine aminotransferase ≤ 3 x ULN (≤ 5x ULN in the presence of liver mets).
    • For patients with hepatocellular carcinoma (HCC) Child Pugh score of ≤ B7.
    • Creatinine < 1.5x ULN
  • Evaluable or measurable disease by RECIST v1.1
  • Patients with active Hepatitis B (defined as Hep B S Ag or DNA positive) need to be on anti-viral therapy while on PRL3-ZUMAB.

Exclusion Criteria:

  • Untreated or symptomatic central nervous system metastases. Patients with treated brain metastases stable for 3 months are eligible to enroll.
  • Major surgical procedures within 28 days prior to enrolment.
  • Pregnant or breast-feeding females.
  • Known HIV infection.
  • Treatment with any of the following anti-cancer therapies prior to the first dose of study drugs within the stated time frames:

    • Prior chemotherapy ≤ 2 weeks of C1 Day 1 of PRL3-ZUMAB.
    • Biological therapy (e.g., antibodies) within a period of time that is ≤ 5 t1/2 or ≤ 3 weeks, whichever is shorter, prior to starting study drug.
    • Continuous or intermittent small molecule therapeutics within a period of time that is ≤ 5 t1/2 or ≤ 3 weeks (whichever is shorter) prior to starting study drug.
    • Any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shortest) prior to starting study drug.
    • Wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug.
  • Patients requiring regular immunosuppressive medication for autoimmune disease or corticosteroid doses of >10mg prednisolone for greater than 2 days
  • Unable to provide informed consent.
  • History of another cancer within the last 2 years, with the exception of

    • Curatively resected non-melanomatous skin cancer,
    • Curatively treated cervical carcinoma in-situ,
    • Prostate cancer treated with leuteinizing hormone-releasing hormone (LH-RH) agonists/pure antagonists for at least 2 months
  • Prior stem cell or bone marrow transplant
  • Vaccinated within 2 weeks from prior to the first administration of PRL3-ZUMAB

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04118114

Layout table for location contacts
Contact: Matthew Ng, MD 6436 8000

Layout table for location information
National Cancer Center Singapore Recruiting
Singapore, Singapore, 169690
Sponsors and Collaborators
National Cancer Centre, Singapore
Layout table for investigator information
Principal Investigator: Matthew Ng, MD National Cancer Centre of Singapore
Layout table for additonal information
Responsible Party: National Cancer Centre, Singapore Identifier: NCT04118114    
Other Study ID Numbers: NCCS-2018-Phase2-PRL3
First Posted: October 8, 2019    Key Record Dates
Last Update Posted: June 13, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases